Graft-Versus-Lymphoma Effect after Allogeneic Peripheral Blood Stem Cell Transplantation for Primary Central Nervous System Lymphoma

References

• Thomas E. D. Kettering Award Lecture: The role of marrow transplantation in the eradication of malignant disease. Cancer 1982; 49: 1963–1969, 1982
   PubMed Web of Science ®Google Scholar
• O'Reilly R. J. Allogeneic bone marrow transplantation: Current status and future directions. Blood 1983; 62: 941–964
   PubMed Web of Science ®Google Scholar
• Barrett A. J., Horowitz M. M., Gale R. P., Biggs J. C., Camitta B. M., Dicke K. A., Gluckman E, Good R. A., Herzig R. H., Lee M. B. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989; 74: 862–871
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sonde P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringden O., Rozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Weiss L., Weigensberg M., Morecki S., Bar S., Cobbold S., Waldmann H., Slavin S. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunology and Immunotherapy 1990; 31: 236–242
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Weiss L., Nagler A., Or R., Naparstek E. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Investigations 1992; 10: 221–227
   PubMed Web of Science ®Google Scholar
• Weiss L., Lubin I., Factorowich I., Lapidot Z., Reich S., Reisner Y., Slavin S. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: Role of cell therapy and recombinant IL-2. Journal of Immunology 1994; 153: 2562–2567
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Shih C. Y., LeFever A. V., Tempelis L. D., Andreani M., Bortin M. M. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. Journal of Immunology 1983; 131: 2050–2058
   PubMed Web of Science ®Google Scholar
• Cohen P., Vourka-Karussis U., Weiss L., Slavin S. Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Journal of Immunology 1993; 151: 4803–4810
   PubMed Web of Science ®Google Scholar
• Collins R. H., Jr., Shpilberg O., Drobyski W. R., Porter D. L., Giralt S., Champlin R., Goodman S. A., Wolff S. N., Hu W., Verfaillie C., List A., Dalton W., Ognoskie N., Chetrit A., Antin J. H., Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology 1997; 15: 433–444
   PubMed Web of Science ®Google Scholar
• Naparstek E., Nagler A., Or R., Kapelushnik J., Slavin S. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation. Clinical Transplants, JM Cecka, PI Terasaki. UCLA Tissue Typing Laboratory, Los Angeles 1996, Chap 24
   Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J., Brautbar C., Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V., Ubertu J., Karanes C., Abella E., Lum A. G., Momin F., Cummings G., Sensenbrenner L. L. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–1055
   PubMed Web of Science ®Google Scholar
• Van Besien K. W., Mehra R. C., Giralt S. A., Kantarjian H. M., Pugh W. C., Khouri I. F., Moon Y., Williams P., Andersson B. S., Przepiorka D. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. American Journal of Medicine 1996; 100: 299–307
   PubMed Web of Science ®Google Scholar
• Tricot G., Vesole D. H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 11961198
   Google Scholar
• Eibl B., Schwaighofer H., Nachbaur D., Marth C., Gachter A., Knapp R., Bock G., Gassner C., Schiller L., Petersen F., Niederwieser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508
   PubMed Web of Science ®Google Scholar
• Rapoport A. P., Rowe J. M., Kouides P. A., Duerst R. A., Abboud C. N., Liesveld J. L., Packman C. H., Eberly S., Sherman M., Tanner M. A. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. Journal of Clinical Oncology 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Ferreri A. J., Reni M., Villa E. Primary central nervous system lymphoma in immunocompetent patients. Cancer Treatment Review 1995; 21: 415–446
   PubMed Web of Science ®Google Scholar
• Fine H. A., Mayer R. J. Primary central nervous system lymphoma. Annals of Internal Medicine 1993; 119: 1093–1110
   PubMed Web of Science ®Google Scholar
• Fine H. A. Treatment of primary central nervous system lymphoma: Still more questions than answers. Blood 1996; 86: 2873–2875
   Web of Science ®Google Scholar
• Chopra R., Goldstone A. H., Pearce R., Philip T., Petersen F., Appelbaum F., De Vol E., Ernst P. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. Journal of Clinical Oncology 1995; 10: 1690–1695
   Google Scholar
• Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Aker M., Gimon Z., Manny N., Sacks T., Tochner Z., Weiss L., Samuel S., Brautbar C., Hale G., Waldman H., Steinberg S. M., Slavin S. T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. British Journal of Haematology 1995; 89: 506–515
   PubMed Web of Science ®Google Scholar
• Johnson B. D., Drobyski W. R., Truitt R. L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplantation 1993; 11: 329–336
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465
   PubMed Web of Science ®Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Experimental Hematology 1995; 23: 1553–1562
   PubMed Web of Science ®Google Scholar
• Kapelushnik J., Nagler A., Or R., Naparstek E., Ackerstein A., Samuel S., Morecki S., Nabet C., Slavin S. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions postallogeneic bone marrow transplantation. Bone Marrow Transplantation 1996; 18: 1153–1156
   PubMed Web of Science ®Google Scholar
• Shlomchik W. D., Emerson S. G. The immunobiology of T cell therapies for leukemias. Acta Haematologica 1996; 96: 189–213
   PubMed Web of Science ®Google Scholar
• Giralt S., Estey E., Albitar M., Van Besien K., Rondon G., Anderlini P., O'Brien S., Khouri I., Gajewski J., Mehra R., Claxton D., Andersson B., Beran M., Przepiorka D., Roller C., Kornblau S., Korbling M., Keating M., Kantarjian H., Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536
   PubMed Web of Science ®Google Scholar
• Bar B. M., Schattenberg A., Mensink E. J., Geurts-Van Kessel A., Smetsers T. F., Knops G. H., Linders E. H., De Witte T. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. Journal of Clinical Oncology 1993; 11: 513–519
   PubMed Web of Science ®Google Scholar
• Drobyski W. R., Roth M. S., Thibodeau S. N., Gottschall J. L. Molecular remission occurring after donor leukecyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplantation 1992; 10: 301–304
   PubMed Web of Science ®Google Scholar
• Drobyski W. R., Keever C. A., Roth M. S., Koethe S., Hanson G., McFadden P., Gottschall J. L., Ash R. C., Van Tuinen P., Horowitz M. M. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318
   PubMed Web of Science ®Google Scholar
• Williams K. C., Hickey W. F. Traffic of hematogenous cells through the central nervous system. Current Topics in Microbiology and Immunology 1995; 202: 221–245
   PubMed Web of Science ®Google Scholar
• Lassmann H., Schmied M., Vass K., Hickey W. F. Bone marrow derived elements and resident microglia in brain inflammation. Glia 1993; 7: 19–24
   PubMed Web of Science ®Google Scholar
• Krivit W., Sung J. H., Shapiro E. G., Lockman L. A. Microglia: The effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplantation 1995; 4: 385–392
   PubMed Web of Science ®Google Scholar